Jet Bio-Filtration(SH:688026)2021-04-29 16:00Financial Performance - The company's operating revenue for 2020 reached ¥503,933,836.45, representing a 103.61% increase compared to ¥247,495,947.02 in 2019[25]. - The net profit attributable to shareholders for 2020 was ¥119,371,464.55, an increase of 80.45% from ¥66,153,234.49 in 2019[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥109,567,050.22, up 98.02% from ¥55,332,144.98 in 2019[25]. - The net cash flow from operating activities for 2020 was ¥187,566,736.11, a significant increase of 207.39% compared to ¥61,018,800.31 in 2019[25]. - As of the end of 2020, the total assets amounted to ¥969,709,074.32, reflecting a 144.03% increase from ¥397,374,061.19 at the end of 2019[25]. - The net assets attributable to shareholders at the end of 2020 were ¥796,893,187.84, which is a 128.92% increase from ¥348,114,100.66 at the end of 2019[25]. - The company achieved a revenue of 503.93 million yuan in the reporting period, representing a year-on-year growth of 103.61%[98]. - Operating profit for the period was 148.17 million yuan, an increase of 93.84% compared to the previous year[98]. - Net profit attributable to the parent company reached 119.37 million yuan, reflecting a year-on-year growth of 80.45%[98]. Dividend Policy - The company plans to distribute a cash dividend of 1.20 CNY per 10 shares, totaling 12 million CNY, which represents 10.05% of the net profit attributable to shareholders for 2020[6]. - The total cash dividend proposed for 2020 is CNY 12 million, which accounts for 10.05% of the net profit attributable to shareholders[165]. - The company has established a cash dividend policy that prioritizes stable and continuous returns to shareholders, with a minimum distribution ratio of 10% of the distributable profit[160]. - The company’s cash dividend distribution ratio may reach 80% for mature stages without major capital expenditures, ensuring shareholder returns while supporting long-term development[161]. - The cumulative distributable profit for the parent company as of December 31, 2020, is CNY 214.37 million[163]. - The company has maintained compliance with dividend principles and policies, ensuring transparency and protection of minority shareholders' rights[164]. Operational Risks and Compliance - The company has detailed various operational risks and corresponding mitigation measures in the report[5]. - The company aims to maintain compliance with the relevant regulations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[20]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a commitment to investors[7]. - The company has not faced any violations in decision-making procedures regarding external guarantees[9]. - There are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company does not have any special arrangements for corporate governance[7]. Research and Development - Research and development expenses accounted for 4.74% of operating revenue, a decrease of 0.34 percentage points, although R&D spending increased by 90.22% year-on-year[29]. - The company applied for a total of 47 patents during the reporting period, including 14 invention patents and 13 PCT international applications, and received 28 new patent authorizations[56]. - R&D investment increased by 90.22% year-on-year, amounting to approximately 9.26 million yuan, primarily due to increased investment in protective product development[61]. - The company has developed technologies that significantly improve cell culture efficiency, including temperature-sensitive surface modifications and 3D cell culture scaffolds[89]. - The company is focusing on the research and development of new products that cater to personalized cell therapy applications[68]. Market Expansion and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through new technologies and research[17]. - The company aims to enhance its market share through ODM sales agreements with well-known biological laboratory service providers[43]. - The company has expanded its protective product line to include medical surgical masks, KN95 masks, FFP2 masks, children's masks, protective clothing, and goggles, all of which have obtained necessary certifications[39]. - The company is committed to enhancing its production capacity for epidemic prevention materials, including masks and protective clothing, to meet government storage directives over the next five years[49]. - The company is actively participating in the national emergency material guarantee system project, developing new products such as positive pressure protective clothing and negative pressure isolation stretchers in response to the global pandemic[157]. Financial Management and Investments - The company has significant investment plans, with expected expenditures reaching or exceeding 30% of the latest audited net assets within the next twelve months[163]. - The company has utilized 191.84 million yuan of the raised funds, accounting for 50.56% of the net amount raised[98]. - The company is focusing on expanding its production capacity to meet the growing demand for biological laboratory consumables[98]. - The company has established a comprehensive quality management system in accordance with ISO 9001:2015 and ISO 13485:2016 standards, ensuring product quality and compliance[92]. Legal and Compliance Issues - The company has disclosed significant litigation matters, with no subsequent developments reported[189]. - A lawsuit involving the wholly-owned subsidiary Baifeier against Guokai Intelligent Technology Co., Ltd. has been initiated, with a claimed advance payment amount of 20,311,900 RMB[189]. - The subsidiary Baifeier has filed a lawsuit against Shenzhen Zhentong Trading Co., Ltd. and Ganzhou Huhuang Freight Forwarding Co., Ltd. for trademark infringement, involving a total value of 663,460 Euros[190]. - The company has not faced any situations leading to delisting or bankruptcy restructuring during the reporting period[189]. Production and Supply Chain - The company has established a strict procurement management system in compliance with ISO 13485 standards for medical device quality management[40]. - The company has implemented advanced automation technology, significantly improving product quality and production efficiency[74]. - The production capacity for centrifuge tubes has increased from 30,000 units per day to 150,000 units per day, a fivefold increase[74]. - The company has established a flexible customization production capability, enhancing its ability to continuously develop high-end consumable products and improve profitability[90]. Shareholder and Stock Management - The company reported a lock-up period of 36 months for shares held prior to the IPO, starting from January 22, 2020[169]. - Shareholders are restricted from transferring or entrusting their shares for 12 months post-IPO, effective from January 22, 2020[169]. - The company will adhere to regulations regarding share reduction, allowing a maximum of 25% of pre-IPO shares to be sold within two years after the lock-up period[171]. - The company has committed to full legal responsibility for any compensation claims arising from share transfers[171].